This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LSX Nordic
Life Science Executive Partnering
19-20 May 2026Radisson Blu Scandinavia Hotel, Copenhagen, Denmark

Martin Carlsson
Associate Professor and Senior Consultant in Endocrinology and Diabetology, and Co-founder at Yazen
Speaker

Profile

  • Doctor specialized in endocrinology/diabetology, internal medicine and clinical chemistry.
  • Medical studies at Karolinska Institutet, Stockholm, doctoral studies in type 2 diabetes and genetics of obesity at Lund University and now associate professor at Linnaeus University with main interests in hypertension, type 2 diabetes, obesity, vitamin D, the metabolic syndrome and digitization of health care.
  • Author of more than 50 scientific articles published in peer-reviewed scientific journals and a range of medical textbooks.
  • Founder of the e-health company Accumbo AB, now renamed Blodtrycksdoktorn, and co-founder and medical manager of the e-health service Yazen Health, which works with obesity.


Yazen is a digital healthcare provider specialising in the treatment of obesity – a chronic disease that requires long-term care. We are currently active in eight countries: Sweden, Norway, Denmark, the Netherlands, the United Kingdom, Switzerland, Germany and Spain. Our team consists of 290 employees, of which 217 work clinically – including 114 licensed physicians. Our unique model combines modern medicines, continuous digital care, your own doctor and support from a full care team consisting of a health coach, dietician, psychologist and physiotherapist. Research shows that this holistic model produces better and more sustainable results than medication alone. More than 44,000 patients are currently undergoing treatment and a total of 47,000 patients have lost over 760 tons together.

Agenda Sessions

  • Beyond the Horizon: Next-Generation GLP-1s, Alternatives, and the Future of Diabetes Care and Metabolic Disorders

    09:10